Contact Us
Contact Us
FREE ASSESSMENT

Drug Diversion Surveillance Value Assessment

Are you looking to develop or improve your drug diversion program but not sure where to begin?

Let us help you develop a personalized business use case that will elevate your drug diversion program with adoption of new technology that supports your business goals and secures executive buy-in.

In your drug diversion surveillance value assessment, we will review:

Drug Diversion Surveillance Value Assessment
This value assessment is free and is done via a 30-min Zoom meeting. At the end of the meeting you will be provided with a copy of the personalized Business Case + Value Assessment for you to use in conversations with stakeholders at your organization.
 
 

How the assessment works ↓

Get Started Now

1

Register

Fill out the form above with your contact information and information for the assessment.

2

Schedule the Assessment

Our expert will be in touch to book a meeting and provide a list of information needed for the meeting.

3

We (Virtually) Meet!

At the meeting, we will discuss key information about your organization, review the findings and follow-up with a a personalized business use case document that you can use in conversations with with your decision makers.

What Our Customers Are Saying

“ One outcome of the product is the decrease in time for the initial case review completion. The second time reduction is a decrease in the time to case resolution. We have had a significant increase in the number of cases we have been able to review by using the platform.”
Manager
April 2022 KLAS Survey*
Protenus Diversion Analytics is great. It has has been very beneficial for our organization. It has helped us a lot with streamlining our diversion time frames and drug diversion monitoring.. I am very pleased with the product.”
Analyst/Coordinator
August 2022 KLAS Survey*
Protenus has largely driven our drug diversion monitoring efforts through product updates and responsiveness to our requests, feedback, and concerns.”
Analyst/Coordinator
March 2022 KLAS Survey*